Another highlight of this year’s ASCO GI Symposium held in San Francisco in January was the update from the IMbrave 151 trial for biliary tract cancer.

Annual scientific meetings are off to a big start in 2023 with the 20 year celebratory ASCO GI Symposium held in San Francisco in January.

Cholangiocarcinoma is rare and difficult to treat with only 1 in 5 people diagnosed surviving beyond five years. However, there have been many recent treatment advances with both immune checkpoint and molecularly targeted therapies.

The potential role for genomic testing to help guide therapy selection in URS was highlighted in an exciting publication from the phase 1 unit of the MD Anderson Cancer Centre.